Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 70 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary ResistanceStatus unknownNCT03666325Phase 2
- Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.CompletedNCT03666273Phase 1
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedNCT03665545Phase 1/2
- IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsTerminatedNCT03665129Phase 1
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerCompletedNCT03661320Phase 3
- PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)CompletedNCT03658447Phase 1/2
- Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520Status unknownNCT03657381Phase 1
- Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseTerminatedNCT03656627Phase 1
- Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsStatus unknownNCT03656094Phase 2
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminatedNCT03655613Phase 1/2
- Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaStatus unknownNCT03655483Phase 2
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1
- Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving DurvalumabActive, not recruitingNCT03653052Phase 2
- Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03652233Phase 1
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2
- Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2
- Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedNCT03645876Phase 2
- Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLCTerminatedNCT03644823Phase 2
- Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerWithdrawnNCT03644589Phase 2
- Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid TumorsCompletedNCT03644056Phase 1
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownNCT03639181Phase 2
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
- Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell CarcinomaCompletedNCT03635164Phase 1
- Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach AdenocarcinomaStatus unknownNCT03631615Phase 2
- Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by ElectroporationTerminatedNCT03630640Phase 2
- Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
- A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedNCT03629756Phase 1
- A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesCompletedNCT03628677Phase 1
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaActive, not recruitingNCT03628209Phase 1
- Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT03626922Phase 1
- Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCCCompletedNCT03624231Phase 2
- Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedNCT03623854Phase 2
- Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.WithdrawnNCT03623776Phase 2
- Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)Status unknownNCT03623581Phase 2
- 1st Line Durvalumab in PS 2 NSCLC PatientsActive, not recruitingNCT03620669Phase 2
- DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLActive, not recruitingNCT03620578Phase 2
- Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder CancerStatus unknownNCT03620435Phase 2
- A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckCompletedNCT03620123Phase 2
- PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03619824Phase 2
- This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersTerminatedNCT03618953Phase 1
- Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell CarcinomaCompletedNCT03618654Early Phase 1
- Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell CanerTerminatedNCT03618134Phase 1/2
- Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window StudyActive, not recruitingNCT03617666Phase 2
- Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCStatus unknownNCT03616691Phase 2
- SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerActive, not recruitingNCT03614949Phase 2
- Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint AtezolizumabCompletedNCT03612791Phase 2
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerActive, not recruitingNCT03610711Phase 1/2
- A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1
- PDR001 Plus Imatinib for Metastatic or Unresectable GISTCompletedNCT03609424Phase 1/2
- Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome SequencingCompletedNCT03608865Phase 2
- Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerStatus unknownNCT03608046Phase 2
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedNCT03605719Phase 1
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.Status unknownNCT03605706Phase 3
- Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
- Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2
- Atezolizumab Trial in Endometrial Cancer - AtTEndCompletedNCT03603184Phase 3
- Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
- A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCStatus unknownNCT03601598Phase 1/2
- Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerActive, not recruitingNCT03601455Phase 2
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1
- Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedNCT03599453Early Phase 1
- PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell CarcinomaWithdrawnNCT03598816Phase 2
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2
- Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerCompletedNCT03598270Phase 3
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1
- Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerActive, not recruitingNCT03595592Phase 3
- Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2
- Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnNCT03592407Phase 2
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2
- TACE-HAIC vs. HAIC for Potentially Resectable HCCStatus unknownNCT03591705Not applicable
- Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue SarcomasCompletedNCT03590210Phase 2
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedNCT03590054Phase 1
- Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell LungCompletedNCT03589547Phase 2
- Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantTerminatedNCT03588936Phase 1
- A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid TumorsCompletedNCT03588650Phase 1
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT03588039Phase 1
- Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
- Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung CancerStatus unknownNCT03585998Phase 2
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
- Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03580694Phase 1
- An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaCompletedNCT03580564Phase 2
- Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2
- Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2
- Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerWithdrawnNCT03576963Phase 1/2
- GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade GliomasCompletedNCT03576612Phase 1
- A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckActive, not recruitingNCT03576417Phase 3
- Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyCompletedNCT03575598Early Phase 1
- Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnNCT03575234Phase 1
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial CancerCompletedNCT03575013Phase 1
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
- Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung CancerWithdrawnNCT03574220Early Phase 1
- Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular CarcinomaCompletedNCT03572582Phase 2
- Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic CancerActive, not recruitingNCT03572400Phase 2
- Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyStatus unknownNCT03569696Phase 2
- Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerCompletedNCT03568097Phase 2